FDA “Progressive Approval” And “Exceptional Approval” Pathways Possible Under Senate Bill

Legislation being drafted by Sen. Kay Hagan, D-N.C., would formalize FDA practices of approving drugs in certain circumstances where the evidence needed for a standard approval cannot be generated.